[Translation] A 12-week prospective, open-label, single-cohort study to evaluate the effects of fluticasone furoate/umeclidinium/vilanterol single inhaler (flutimervir inhalation powder) on symptomatic chronic Real-world effectiveness in patients with obstructive pulmonary disease (COPD)
主要目的: 本研究的主要目的是评估第 12 周时氟替美维吸入粉雾剂(全再乐)对有症状的 COPD 受试者健康状况的有效性。
次要目的: (1)评估第 12 周时氟替美维吸入粉雾剂(全再乐)对有症状的 COPD 受试者呼吸困难的有效性。(2)评估第 12 周时氟替美维吸入粉雾剂(全再乐)对有症状的 COPD 受试者肺功能的有效性。(3)评估第 4 周时氟替美维吸入粉雾剂(全再乐)对有症状的 COPD 受试者健康状况的有效性。
安全性目的:安全性目的是收集使用氟替美维吸入粉雾剂(全再乐)的受试者的安全性信息。
[Translation] Primary objective: The primary objective of this study was to evaluate the efficacy of flutimervir inhalation powder (Quanzai) at week 12 on the health status of subjects with symptomatic COPD.
Secondary objectives: (1) To evaluate the efficacy of flutimervir inhalation powder inhalation powder (Quanzai Le) on dyspnea in symptomatic COPD subjects at week 12. (2) To evaluate the efficacy of flutimervir inhalation powder inhalation powder (Quanzai Le) on lung function in symptomatic COPD subjects at week 12. (3) To evaluate the efficacy of flutimervir inhalation powder spray (Quanzai Le) on the health status of symptomatic COPD subjects at week 4.
Safety Objective: The safety objective is to collect safety information from subjects using Flutimervir inhalation powder (Quanzai Lexu).